Hypercalcemia of Malignancy

Definition

Hypercalcemia of malignancy (HCM) is clinically important cancer-associated elevation of serum calcium. Across the available studies, hypercalcemia has been operationalized using total calcium, albumin-corrected calcium, persistence over time, or severity thresholds rather than one universally consistent definition. In a contemporary head and neck squamous-cell carcinoma (HNSCC) cohort, hypercalcemia at diagnosis was defined as an albumin-corrected serum calcium >2.6 mmol/L (10.4 mg/dL). ^[8]B3b A primary-care cancer-risk study used calcium ≥2.6 mmol/L as its principal threshold. ^[4]B3b A pediatric solid-tumor study required sustained serum calcium ≥11.5 mg/dL for >1 week, thereby identifying prolonged rather than transient hypercalcemia. ^[16]B3b In a hospitalized-patient mortality study, albumin-corrected calcium was categorized as mild hypercalcemia at 10.5–11.5 mg/dL and marked hypercalcemia at >11.5 mg/dL. ^[155]

HCM should therefore be interpreted in clinical context and distinguished from other causes of hypercalcemia, including primary hyperparathyroidism and treatment-related rebound. In a US military-veteran cohort of 212 patients with hypercalcemia, 59 patients (28%) had malignant disease, demonstrating that malignancy is a major but not exclusive cause of elevated calcium. ^[154]C Primary hyperparathyroidism was specifically represented among the alternative diagnoses in that cohort. ^[154]C A surgical study of 762 patients with primary hyperparathyroidism evaluated how calcium severity and other clinical variables affect intraoperative parathyroid-hormone monitoring, reinforcing the importance of considering primary parathyroid disease when attributing hypercalcemia to cancer. ^[152]

Mechanistically, malignancy-associated hypercalcemia may reflect humoral effects, skeletal destruction, or both. In newly diagnosed multiple myeloma, hypercalcemia was specifically evaluated as arising from “humoral effects and bone damage,” and its presence was associated with adverse clinical and laboratory features. ^[7]B3b Bone metastasis is also clinically relevant because hypercalcemia is classified as a skeletal-related event in patients with metastatic breast cancer. ^[10]B3b Conversely, cessation of denosumab can produce rebound hypercalcemia independently of new tumor activity: among 21 patients with bone-metastatic breast cancer who stopped denosumab, 6 (28.6%) developed hypercalcemia. ^[13]B3b

Overall epidemiology

HCM is reported most often in patients with advanced malignancy. A contemporary HNSCC study describes hypercalcemia as the most common metabolic disorder in cancer and estimates that it affects approximately 10%–20% of patients with advanced malignancies; the study assessed locally advanced or metastatic HNSCC at treatment initiation. ^[8]B3b In a large US electronic-health-record analysis involving approximately 569,000 oncology patients treated at 565 outpatient sites, HCM prevalence was estimated by cancer type and CTCAE grade using serum calcium and albumin measurements. ^[1]B3b That analysis reported the highest rates in multiple myeloma and the lowest rates in colorectal and prostate cancer, although prevalence varies according to tumor mix, disease stage, laboratory definition, and ascertainment method. ^[1]B3b

Hypercalcemia in primary care is also a marker of occult or subsequently diagnosed cancer. Among 54,267 patients aged 40 years or older with calcium results, 1,674 (3%) had calcium ≥2.6 mmol/L. ^[4]B3b Hypercalcemia was associated with cancer diagnosed during the subsequent year, with stronger association in men than women: odds ratio 2.92 in men and 1.86 in women. ^[4]B3b The corresponding positive predictive value for cancer was 11.5% in men and 4.1% in women, despite hypercalcemia being more common among women in that population. ^[4]B3b

Tumor-specific patterns

Multiple myeloma is one of the malignancies most strongly associated with HCM. In a retrospective cohort of 357 patients with newly diagnosed symptomatic multiple myeloma, 16.8% presented with hypercalcemia at diagnosis. ^[7]B3b Hypercalcemia was associated with higher β2-microglobulin, creatinine, phosphorus, uric acid, and procollagen I N-terminal propeptide levels, and the study concluded that both humoral effects and bone damage contribute to adverse outcomes. ^[7]B3b An earlier cohort of 338 newly diagnosed stage II–III myeloma patients reported bone lesions in 72.2%, providing clinical context for the skeletal component of calcium dysregulation in myeloma. ^[112]B2b

HCM is also relatively frequent in diffuse large B-cell lymphoma (DLBCL). In a cohort of 305 patients, hypercalcemia at diagnosis, defined as calcium >10.5 mg/dL, occurred in 23% of de novo DLBCL and 26% of transformed indolent lymphoma. ^[9]B3b In de novo DLBCL, hypercalcemia was strongly associated with high-risk disease features and a short interval from diagnosis to treatment. ^[9]B3b

Squamous-cell malignancies represent another important clinical phenotype. A single-center series of 220 patients with biopsy-proven squamous-cell carcinoma and a first episode of cancer-associated hypercalcemia reported a median age of 55 years and median survival of only 64 days from the hypercalcemic episode. ^[14]B3b Corrected calcium >3.0 mmol/L, hypoalbuminemia, and brain metastases were independent adverse prognostic factors. ^[14]B3b A separate study of 260 patients treated with intravenous diphosphonates likewise reported median survival of 64 days; corrected calcium >2.83 mmol/L, albumin <35.5, squamous-cell carcinoma, bone metastases, and liver involvement were associated with poorer survival. ^[111]C4

HCM is uncommon in children with solid tumors. A 25-year retrospective pediatric study identified 39 patients younger than 21 years with a solid tumor and prolonged hypercalcemia using the threshold of ≥11.5 mg/dL for >1 week; the investigators emphasized that pediatric hypercalcemia is rare and may cause severe renal insufficiency and osteoporosis. ^[16]B3b Rare tumor entities may nonetheless present in young patients: small-cell carcinoma of the ovary, hypercalcemic type, is described as a rare, rapidly lethal disease affecting young women. ^[113]C4

Clinical severity and associated presentations

Severe HCM may require renal replacement therapy. A retrospective nephrology-unit study evaluated adults with severe hypercalcemia requiring acute hemodialysis over 84 months and examined etiologies, clinical and biochemical presentation, mortality, and changes during the COVID-19 pandemic. ^[6]B3b HCM can also present with acute pancreatitis, although this combination is uncommon: a systematic review identified 37 published cases, with mean presenting corrected calcium of 14.5 mg/dL; parathyroid carcinoma and multiple myeloma each accounted for 21.6% of reported cases. ^[15]C4 In hospitalized populations, hypercalcemia is associated with increased mortality risk, supporting its use as a marker of serious underlying illness even when malignancy is not the cause. ^[155] A modern Australian tertiary-hospital study similarly examined the causes and mortality associated with inpatient hypercalcemia, reflecting changing contemporary patterns as the prevalence of malignancy and other underlying diseases evolves. ^[156]

Overview

Hypercalcemia of malignancy (HCM) is a metabolic complication of advanced cancer and is reported in approximately 10%–20% of adults with advanced malignancies. ^[8]B3b It is a palliative-care emergency because severe hypercalcemia can produce multisystem complications and is associated with poor prognosis. ^[162] In children, HCM is substantially less frequent, occurring in <1% of pediatric cancer cases, with reported estimates of 0.4%–1.0%. ^[32]D5 Pediatric HCM is more often associated with hematologic malignancy, particularly acute lymphoblastic leukemia, whereas adult cases are more commonly linked to solid tumors. ^[32]D5

Principal malignant mechanisms

The major recognized mechanism is humoral hypercalcemia of malignancy (HHM), in which tumor-derived parathyroid hormone-related protein (PTHrP) increases serum calcium. ^[24]C4 PTHrP is produced physiologically by normal breast epithelial cells but can also be produced by breast and other cancers. ^[26]B2a It shares structural similarity with parathyroid hormone (PTH) and binds the same receptor, thereby promoting PTH-like calcium-regulatory effects. ^[24]C4 PTHrP-associated HHM is reported across gynecologic malignancies, although the available literature is heterogeneous and largely consists of reported cases mapped in a scoping review. ^[24]C4

A second mechanism is local skeletal disease, particularly tumor-driven remodeling in bone metastases. ^[22]D5 Breast cancer cells can release PTHrP, receptor activator of nuclear factor-κB ligand (RANKL), and transforming growth factor-β (TGF-β), disrupting bone homeostasis through osteoclast activation and osteoblast dysregulation. ^[22]D5 This creates a reinforcing tumor–bone cycle in which the bone microenvironment supports tumor persistence while tumor-derived signals increase skeletal calcium release. ^[22]D5 Breast cancer bone metastases account for approximately 70% of metastatic breast cancer cases, making this pathway clinically important in that disease. ^[22]D5

Not all malignancy-associated hypercalcemia conforms to classical osteoclast-mediated osteolysis. A reported patient with high-risk biclonal IgA plasma-cell myeloma developed extreme PTH-independent hypercalcemia, with calcium reaching 17.4 mg/dL, hyperphosphatemia, no marrow osteoclasts, and no osteolytic lesions. ^[160]C The authors characterized the episode as a rare non-osteoclastic bone-remodeling mechanism; hypercalcemia resolved with supportive treatment alone within eight days, although the temporal relationship to a second Moderna mRNA-1273 vaccine dose was reported and does not establish causation. ^[160]C

Tumor types and clinical associations

HCM is described in advanced head and neck squamous-cell carcinoma, where hypercalcemia at diagnosis was defined as albumin-corrected calcium >2.6 mmol/L (10.4 mg/dL). ^[8]B3b In a contemporary pediatric solid-tumor cohort, prolonged hypercalcemia was defined as sustained serum calcium ≥11.5 mg/dL for >1 week; the study identified 39 hospitalized patients younger than 21 years, underscoring the rarity of this presentation. ^[16]B3b In advanced cancer patients receiving palliative care, the prevalence of hypercalcemia and its associated clinical factors have been evaluated in a 155-patient Bangladeshi cohort, although prevalence estimates from that setting should not be generalized to all cancer populations. ^[162]

PTHrP elevation is not synonymous with malignancy. In a retrospective study of 236 patients with hypercalcemia and elevated PTHrP above sex-specific thresholds—>2.3 pmol/L in men and >3.4 pmol/L in women—only 58 had known cancer; the remainder had defined nonmalignant diagnoses. ^[33]B2b Thus, PTHrP results must be interpreted with the clinical context rather than used as an isolated diagnostic confirmation of HCM. ^[33]B2b In breast cancer, a 2026 systematic review and meta-analyses specifically evaluated associations between tumor or circulating PTHrP, tumor characteristics, calcium levels, relapse, and survival, reflecting ongoing uncertainty about whether PTHrP is solely a mediator of hypercalcemia or also a marker of tumor biology. ^[26]B2a

Important malignant and nonmalignant mimics

Parathyroid carcinoma is a rare malignant endocrine tumor that causes severe hypercalcemia through excessive PTH secretion and therefore represents a PTH-dependent malignant cause distinct from typical PTHrP-mediated HHM. ^[34]C4 Its clinical manifestations may include skeletal fragility, nephrolithiasis, neuromuscular symptoms, cardiovascular disturbances, and neurocognitive abnormalities. ^[34]C4 Primary hyperparathyroidism from parathyroid adenoma remains an important alternative explanation for hypercalcemia; a large retrospective series of 561 surgical patients included 78 giant adenomas weighing >3.5 g, with bone pain and renal calculi among common presentations. ^[159]

Disordered vitamin D metabolism can also mimic or compound malignant hypercalcemia. Loss-of-function CYP24A1 mutations reduce degradation of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 and may cause hypercalcemia with nephrocalcinosis and nephrolithiasis, including in patients who also have primary hyperparathyroidism. ^[52]C4 Conversely, pharmacologic 1,25-dihydroxyvitamin D3 exposure can itself cause hypercalcemia at doses needed for anticancer activity, limiting clinical translation of vitamin-D-based strategies. ^[163]D

Emerging tumor-microenvironment links

Hypoxic cancer-associated fibroblasts in colorectal cancer have been investigated in relation to a PTHrP–vitamin D–renin–angiotensin-system axis, suggesting that stromal signaling may influence tumor biology, although these findings do not establish a direct cause of HCM in patients. ^[21]D5 In non-small-cell lung cancer, hypercalcemia was associated with altered levels of selected circulating cytokines but not with a significant difference in peripheral lymphocyte distribution, supporting an association between calcium disturbances and systemic immune signaling rather than proving a causal immune mechanism. ^[39]C4

These pathogenic mechanisms disrupt membrane excitability, renal concentrating ability, and gastrointestinal motility, producing a symptom complex that is often insidious and frequently misattributed to cancer progression or chemotherapy toxicity. The presentation spans a spectrum from asymptomatic laboratory abnormalities to life-threatening crisis, with the severity correlating with both the rate of rise and the absolute calcium level.

Presenting Symptoms

Symptoms typically evolve over 1-2 weeks, but severe hypercalcemia (serum calcium > 14 mg/dL [3.5 mmol/L]) can manifest acutely over hours to days. The classic triad, gastrointestinal, renal, and neurological, appears in most symptomatic patients:

• Gastrointestinal: Nausea, vomiting, anorexia, constipation (often severe, mimicking obstruction).
• Renal: Polyuria, polydipsia, nocturia, leading to dehydration and volume contraction.
• Neurological: Fatigue, lethargy, confusion, and in severe cases, stupor or coma.
• Musculoskeletal: Generalized weakness, bone pain, and myalgias.

Serum calcium > 12 mg/dL (3.0 mmol/L) consistently provokes symptoms, while > 14 mg/dL (3.5 mmol/L) portends encephalopathy and cardiac risk. In a cohort of 350 neuroblastoma patients treated with 13-cis-retinoic acid, hypercalcemia (grades 1-4) occurred in 22.3%, and symptoms were “frequent but moderate” ^[42]B2b.

Neurological Examination Findings

Perform a systematic neuromuscular exam, focusing on:

• Motor: Proximal muscle weakness, test by asking the patient to rise from a chair without using arms; inability suggests clinically significant weakness. Hypotonia may be present.
• Reflexes: Deep tendon reflexes are often depressed or absent.
• Sensory: Usually intact; no sensory level is expected.
• Cranial nerves: Typically normal unless encephalopathy has progressed.
• Autonomic: Orthostatic hypotension (due to hypovolemia from polyuria) is common; check supine and standing blood pressure.
• Mental status: Assess level of consciousness, attention, and orientation. The earliest sign may be subtle cognitive slowing.

Phenotypic Variants

Red Flags

Symptoms that mandate immediate action:

• Altered mental status (confusion, stupor, coma)
• Seizures
• Cardiac arrhythmias (ECG may show shortened QT interval, widening QRS)
• Acute kidney injury (often from prerenal azotemia superimposed on hypercalcemic nephropathy)
• Severe dehydration with orthostatic hypotension

Urgent intervention is indicated for serum calcium > 14 mg/dL (3.5 mmol/L) or the presence of any neurological symptom.

ECG Findings

Hypercalcemia shortens the QT interval by reducing the plateau phase of the action potential. This is a consistent finding and can be a clue to the diagnosis:

Atypical Presentations

Hypercalcemia of malignancy is frequently missed when it presents as:

• Isolated psychiatric symptoms: Depression, anxiety, or psychosis without other features.
• Fatigue and weakness: Mistaken for cancer cachexia or chemotherapy side effects.
• Chronic constipation: Especially in patients on opioids, the contribution of hypercalcemia may be overlooked.
• Bone pain: In patients with skeletal metastases, hypercalcemia may be attributed solely to the metastases. (Brown tumors from hyperparathyroidism are a mimic, but rarely occur in malignancy ^[41]C4.)

All three cases of vitamin D intoxication reported by Anık et al. presented with hypercalcemia symptoms, reinforcing that the presentation is nonspecific and requires a high index of suspicion ^[45]C4.

Pearl: When a patient with cancer develops new-onset confusion, constipation, or polyuria, check a serum calcium before attributing symptoms to disease progression, hypercalcemia is reversible and its recognition changes management .

Confirm that hypercalcemia is genuine

Begin by repeating the serum calcium measurement and determining its clinical severity. Total calcium should be interpreted with the albumin concentration; albumin-corrected calcium is specifically used in the biochemical assessment of primary hyperparathyroidism (PHPT). ^[167] When albumin correction is unreliable or the clinical picture is discordant, measure ionized calcium directly. In a pediatric PHPT case, both total and ionized calcium were elevated, illustrating the value of confirming biologically active calcium. ^[55]C4 Assess the duration and trajectory of hypercalcemia, because sustained or increasing calcium concentrations may provide information about disease stage and prognosis in malignancy-associated hypercalcemia. ^[32]D5

A sustained serum calcium of at least 11.5 mg/dL for more than 1 week was used to define prolonged hypercalcemia in a pediatric solid-tumor cohort. ^[16]B3b Severe symptomatic hypercalcemia should be treated as a metabolic emergency while the diagnostic evaluation proceeds; HCM is associated with substantial morbidity and mortality, and timely identification is emphasized in contemporary reviews. ^[29]D5 Symptoms may be nonspecific, and severe HCM can present with confusion, deterioration in general condition, or other systemic manifestations. ^[54]C4

Use PTH to establish the biochemical branch point

Measure intact PTH early. Hypercalcemia with an elevated or inappropriately non-suppressed PTH supports a PTH-dependent process, particularly PHPT, whereas hypercalcemia with suppressed PTH directs evaluation toward malignancy and other PTH-independent causes. This distinction is illustrated by PHPT cohorts in which calcium, phosphorus, and PTH are assessed together, and by reported cases of hypercalcemia with elevated PTH and hypophosphatemia. ^[167][170]C

For suspected PHPT, repeat calcium and PTH measurements and evaluate phosphorus, magnesium, 25-hydroxyvitamin D, alkaline phosphatase, renal function, and urinary calcium. These variables were included in contemporary biochemical evaluations of asymptomatic and normocalcemic PHPT. ^[167][168] Normocalcemic PHPT should not be diagnosed from an isolated elevated PTH: the diagnosis requires persistently elevated PTH with normal calcium after exclusion of secondary causes, including vitamin D deficiency and renal impairment. ^[168]

Consider familial hypocalciuric hypercalcemia when hypercalcemia is mild or longstanding, particularly when urinary calcium excretion is low or the clinical history suggests familial disease. Familial hypocalciuric hypercalcemia may coexist with other endocrine disorders and can complicate interpretation of hypercalcemia. ^[171]C Persistent hypercalcemia after parathyroid surgery should prompt reassessment for residual or multigland PHPT, alternative causes, or rare disorders of vitamin D metabolism; CYP24A1 loss-of-function can cause hypercalcemia with nephrocalcinosis and nephrolithiasis because of impaired degradation of vitamin D metabolites. ^[52]C4

Evaluate PTH-independent hypercalcemia for malignancy

If PTH is suppressed, assess for HCM using the clinical context, cancer history, examination, blood count, renal function, phosphorus, and targeted testing for PTH-related peptide (PTHrP), vitamin D metabolites, and skeletal disease. HCM is a recognized complication of advanced cancer and is associated with poor prognosis. ^[162] In adults, solid tumors are a major context for HCM, whereas pediatric HCM is uncommon and is more often associated with hematologic malignancies. ^[32]D5

PTHrP supports humoral HCM but is not diagnostic of cancer by itself. A contemporary retrospective study enrolled 236 patients with hypercalcemia and elevated PTHrP above 2.3 pmol/L in men or 3.4 pmol/L in women; only 58 had known cancer, while the remainder had defined nonmalignant diagnoses. ^[33]B2b Therefore, an elevated PTHrP result should be interpreted with the calcium–PTH pattern and the overall clinical assessment rather than treated as proof of malignancy. ^[33]B2b

Search for skeletal involvement when symptoms, examination, laboratory findings, or cancer history raise concern. Imaging may include directed radiography or cross-sectional imaging, with additional staging studies guided by the suspected primary tumor. Extensive osteolytic skull lesions accompanied severe hypercalcemia in a reported lung-carcinoma presentation, demonstrating that imaging can identify a skeletal mechanism and reveal the underlying malignancy. ^[54]C4

Account for hematologic and plasma-cell disorders

In patients with monoclonal gammopathy, hypercalcemia should not automatically be attributed to progression to multiple myeloma. In an MGUS screening cohort of 2,546 individuals, 191 (7.5%) developed hypercalcemia at least once and 93 had persistent hypercalcemia; multiple myeloma was identified in only 3 participants with persistent hypercalcemia, all of whom had concurrent bone disease. ^[46]B2b Persistent hypercalcemia in MGUS therefore warrants evaluation for myeloma—particularly skeletal imaging and assessment for other myeloma features—but also requires investigation of unrelated endocrine, renal, medication-related, and vitamin D–mediated causes. ^{[46]B2b[52]C4}

Consider special populations and mimics

In children, maintain a broad differential because HCM occurs in fewer than 1% of pediatric cancer cases, with reported incidence of 0.4%–1.0%; hematologic malignancies, especially acute lymphoblastic leukemia, are prominent associations. ^[32]D5 A pediatric solid-tumor cohort defined prolonged hypercalcemia prospectively and documented renal insufficiency and osteoporosis as important potential consequences. ^[16]B3b

In chronic kidney disease, distinguish secondary from tertiary hyperparathyroidism using serial calcium, phosphorus, PTH, vitamin D status, renal history, and parathyroid localization when indicated; overlapping biochemical features can make this distinction difficult. ^[51]C4 Parathyroid imaging is a localization tool rather than a substitute for biochemical diagnosis. Discordant studies occur: a parathyroid adenoma was detected by 4-dimensional CT but not by sestamibi scanning in a child with persistent PHPT. ^[55]C4 If PHPT is biochemically convincing but localization is negative, consider ectopic, mediastinal, or multigland disease. ^[51]C4[55]C4 Severe PTH-mediated hypercalcemia should also raise concern for parathyroid carcinoma, a rare malignancy characterized by unregulated PTH secretion and often severe hypercalcemia. ^[48]D5

Scope and evidence limitations

The supplied evidence does not include a randomized trial, prospective cohort, or systematic review specifically evaluating the emergency treatment of hypercalcemia of malignancy (HCM), nor does it provide comparative evidence for intravenous fluids, calcitonin, glucocorticoids, dialysis, or dosing schedules for acute calcium reduction. The available evidence concerns antiresorptive therapy for skeletal complications, bone health, or medication-related osteonecrosis of the jaw (MRONJ), so use in HCM must be regarded as extrapolative rather than directly supported by these references ^{[61]A1a[174][175][60]A1b}. The other supplied reports address pancreatic surgery, prostate-specific antigen kinetics, epcoritamab-associated cytokine-release syndrome, thyroid disease, or unrelated diagnostic and surgical topics and do not inform acute HCM management ^{[65]A1b[64]B2b[74]B2b[77]B2b[177][178]C[179][180]}.

Immediate assessment and stabilization

Patients with suspected HCM should undergo urgent clinical assessment of neurologic, gastrointestinal, renal, and cardiovascular manifestations, with severity determined from the corrected or ionized calcium concentration, symptoms, renal function, hydration status, and rate of rise. However, none of the permitted references reports validated acute-care thresholds or outcome data for this approach; therefore, local emergency oncology or endocrine protocols should determine the precise triage and monitoring pathway ^[61]A1a[174].

Initial management should simultaneously address volume status, medication contributors, the underlying malignancy, and the need for a rapid antiresorptive intervention. The permitted evidence does not establish the efficacy or safety of any specific crystalloid regimen, loop diuretic strategy, calcitonin regimen, glucocorticoid regimen, or renal replacement strategy in HCM ^[61]A1a[174]. A loop diuretic should therefore not be presented as routine calcium-lowering therapy on the basis of the supplied literature alone ^[61]A1a[174].

Antiresorptive therapy

Antiresorptives are the principal disease-directed treatment class supported indirectly by the supplied cancer literature. In breast-cancer bone metastases, denosumab and bisphosphonates were evaluated for skeletal-related events, including pain, fractures, and radiation or surgery to bone; a 2026 systematic review and meta-analysis included five publications representing four unique studies, comprising three randomized trials and one retrospective cohort ^[61]A1a. A separate network meta-analysis included 22 studies and 14,934 patients with breast-cancer bone metastases and evaluated pamidronate, zoledronate, clodronate, and ibandronate for skeletal-related outcomes ^[175]. These studies concern prevention or management of skeletal complications rather than acute HCM, and their results should not be interpreted as direct evidence of superiority for emergency calcium reduction ^[61]A1a[175].

Denosumab has also been studied in a phase 2 single-arm trial with pembrolizumab in pretreated advanced clear-cell renal-cell carcinoma, using 120 mg subcutaneously on days 1, 8, and 22, followed by every-3-week administration until progression, unacceptable toxicity, or a maximum of 24 months ^[62]C4. This schedule was an oncology trial regimen and is not evidence for acute HCM dosing or for combining denosumab with pembrolizumab specifically to lower calcium ^[62]C4.

In men with non-metastatic prostate cancer receiving androgen-deprivation therapy, a systematic review identified 26 randomized controlled trials, including 17 intravenous-bisphosphonate trials, five oral-bisphosphonate trials, and two denosumab trials, with two trials including both treatment classes ^[174]. The review evaluated bone health and fractures rather than HCM; oral bisphosphonates had no demonstrated effect on 12-month fracture incidence, with RR 0.57 (95% CI 0.10–3.23) and very-low-certainty evidence ^[174]. These findings do not support oral bisphosphonates as acute treatment for HCM ^[174].

Renal, dental, and metabolic precautions

Choice and administration of an antiresorptive should include renal, electrolyte, dental, and treatment-goal review, but the supplied abstracts do not provide a complete acute-HCM renal dosing algorithm or comparative guidance for patients with severe kidney dysfunction ^{[61]A1a[174][175]}. In metastatic hormone-sensitive prostate cancer, a prospective phase II study assessed zoledronic acid alongside androgen deprivation and enzalutamide using bone-density, trabecular-score, alkaline-phosphatase, and CTX outcomes over 18 months; this was a bone-health study and not an acute-calcium study ^[60]A1b.

MRONJ is a clinically important toxicity when potent antiresorptives are used in oncology. A retrospective breast-cancer cohort compared patients who developed MRONJ after zoledronic acid or denosumab exposure and specifically examined drug-related clinical characteristics ^[63]B2b. In a multiple-myeloma dental-extraction cohort, 13 of 320 patients (4.1%) developed MRONJ after pre-autologous-transplant extractions; periodontal disease was the most common reason for extraction among affected patients ^[176]. Conservative-management data found mean sequestrum formation and detection at 6.82 ± 5.44 months after the dental procedure ^[76]C4. These findings support dental-risk assessment and avoidance of unnecessary invasive dental procedures, but they do not justify delaying urgent calcium-lowering therapy when HCM is life-threatening ^{[63]B2b[76]C4[176]}.

Practical conclusion

For acute HCM, stabilize and monitor the patient urgently, investigate the malignancy-related mechanism and reversible contributors, and involve oncology, endocrinology, nephrology, and dental services when appropriate. Within the permitted evidence base, antiresorptives are supported for cancer-associated skeletal disease but not directly validated for emergency HCM; drug selection, timing, and monitoring must therefore follow current institutional protocols and product-specific safety guidance rather than the studies cited here ^{[61]A1a[174][175]}.

Evidence boundaries

The supplied literature does not provide a randomized trial of long-term or maintenance treatment specifically for hypercalcemia of malignancy (HCM), nor does it establish a calcium-directed maintenance schedule, duration, biochemical target, or stopping rule. Most references evaluate maintenance strategies for the underlying cancer rather than prevention or treatment of recurrent HCM. Accordingly, maintenance decisions for HCM should not be inferred from these studies without disease-specific clinical assessment. [183-200]

Cancer-directed maintenance and relevance to HCM

In locally advanced hepatocellular carcinoma without extrahepatic metastasis, TALENTOP evaluated liver resection after induction atezolizumab plus bevacizumab against maintenance systemic therapy in treatment-naive patients with macrovascular invasion; the available abstract identifies this as a multicentre, open-label, randomized phase 3 trial but does not provide outcome data in the supplied excerpt. ^[183] In standard-risk, newly diagnosed multiple myeloma patients not undergoing upfront autologous transplantation, a phase 3 trial compared continuous lenalidomide maintenance with a fixed 2-year course after proteasome-inhibitor/lenalidomide induction; the study was designed around overall survival, but the supplied abstract does not report the final comparative results. ^[90]A1b

For advanced or recurrent endometrial cancer, the RUBY Part 2 study evaluated adding niraparib to dostarlimab maintenance after dostarlimab plus carboplatin-paclitaxel, compared with placebo maintenance after placebo plus chemotherapy. ^[184] In newly diagnosed advanced ovarian cancer, PRIMA evaluated first-line niraparib maintenance versus placebo, with updated patient-reported quality-of-life analyses examining longitudinal symptoms, health-related quality of life, and the effect of disease progression. ^[185] In advanced urothelial carcinoma without progression after first-line platinum chemotherapy, JAVELIN Bladder 100 compared avelumab plus best supportive care with best supportive care alone; exploratory long-term analyses addressed patients with BMI ≥30 kg/m² or controlled diabetes mellitus. ^[188]

Other cited studies similarly concern oncologic disease control rather than HCM. A phase 3 trial evaluated quizartinib with induction and consolidation chemotherapy and as maintenance monotherapy in newly diagnosed FLT3-ITD-negative acute myeloid leukemia; the supplied report is a study-design publication. ^[189] A systematic review and network meta-analysis in newly diagnosed multiple myeloma found that lenalidomide, proteasome inhibitors, and CD38 antibodies improved progression-free survival, while an overall-survival benefit appeared mainly with lenalidomide in transplant-eligible patients; these findings address myeloma maintenance selection, not calcium control. ^[190] A real-world extensive-stage small-cell lung cancer analysis identified maintenance therapy, liver metastasis, albumin, and neutrophil-to-lymphocyte ratio as prognostic variables in patients receiving serplulimab-based immunochemotherapy, but it was retrospective and prognostic rather than an HCM intervention study. ^[191]

RANKL inhibition and calcium safety considerations

The closest mechanistic evidence is a single-arm phase 2 study in pretreated advanced clear-cell renal-cell carcinoma, in which pembrolizumab was combined with denosumab 120 mg subcutaneously on days 1, 8, and 22, then every 3 weeks until progression, unacceptable toxicity, or a maximum of 24 months. The study investigated antitumor activity and safety, not denosumab as treatment or maintenance for HCM; therefore, it cannot establish the appropriate denosumab dose, interval, duration, or rechallenge strategy for malignancy-associated hypercalcemia. ^[62]C4

Investigational maintenance approaches

A phase 2 single-arm study enrolled 60 previously untreated extensive-stage small-cell lung cancer patients to evaluate durvalumab plus olaparib as maintenance after platinum-etoposide therapy; its purpose was to assess antitumor efficacy and safety, not calcium outcomes. ^[193] A phase Ib-II single-arm VENEZOLUNG trial is investigating autologous tumor-lysate-pulsed dendritic-cell vaccination with atezolizumab as maintenance in extensive-stage small-cell lung cancer. ^[200]C Olaparib maintenance was also studied in a prospective phase IIIb Asian cohort with platinum-sensitive recurrent ovarian cancer, with treatment continued until progression or unacceptable toxicity and long-term safety as an important objective. ^[194]

The remaining reports provide contextual rather than therapeutic evidence for HCM maintenance. A retrospective post-transplant AML/MDS study examined venetoclax blood concentrations during venetoclax plus decitabine maintenance and their associations with efficacy and toxicity. ^[195] A claims-based study assessed healthcare utilization and costs after allogeneic transplantation among AML patients who did or did not initiate post-transplant maintenance. ^[196] Retrospective ovarian-cancer analyses examined whether chemotherapy response score predicts benefit from PARP-inhibitor maintenance, outcomes in primary platinum-resistant disease, and symptom burden during first-line maintenance; these studies do not evaluate calcium levels or HCM recurrence. [197-199] A randomized trial of ivonescimab plus chemotherapy and a randomized trial of aumolertinib with or without platinum chemotherapy address treatment after EGFR-TKI exposure or first-line EGFR-mutated non-small-cell lung cancer, respectively, rather than maintenance management of HCM. ^[186][187]

Practical conclusion

Based on these references, long-term HCM management remains an evidence gap. Cancer maintenance therapy may influence the risk of future HCM indirectly through tumor control, but none of the supplied studies validates maintenance therapy solely to prevent recurrent HCM. Denosumab should not be selected or continued for this purpose on the basis of the renal-cell-carcinoma study alone. [62,183-200]

Children and adolescents

Pediatric hypercalcemia requires an etiologic diagnosis before treatment is attributed to malignancy, because reported causes include malignancy, ketogenic diet, and Williams syndrome. In a multicenter pediatric series, patients ranged from 2 months to 16 years, with peak calcium concentrations of 3.29–5.04 mmol/L; intravenous fluids, calcitonin, and glucocorticoids had been tried before denosumab, and all patients received multiple denosumab doses. ^[101]C4 The report supports specialist use of denosumab when conventional therapy is inadequate, but the evidence is limited to a case series and includes heterogeneous, nonmalignant causes. ^[101]C4

Autosomal dominant hypocalcemia type 1 is not a malignancy-associated disorder but is an important pediatric differential because activating CASR variants cause PTH suppression and abnormal renal calcium handling. In five genetically confirmed children refractory to standard therapy, continuous subcutaneous PTH(1-34) infusion was evaluated over as long as 11 years; standard therapy was associated with renal calcium wasting, hypercalciuria, nephrocalcinosis, and potential renal impairment. ^[201]C PTH infusion should therefore be considered only in specialized management of refractory genetic hypoparathyroid disorders, not as routine treatment for hypercalcemia of malignancy. ^[201]C

Pregnancy

Severe hypercalcemia in pregnancy may be caused by primary hyperparathyroidism rather than malignancy. A 32-year-old woman developed acute pancreatitis near term; after cesarean delivery, calcium remained persistently above 4.0 mmol/L, transient responses to calcium-lowering interventions were followed by recurrence, and PTH was 1,404 pg/mL. Imaging identified a parathyroid lesion, and parathyroid carcinoma was diagnosed. ^[98]C4 Persistent or refractory hypercalcemia with pancreatitis in pregnancy should prompt measurement of PTH and expedited endocrine-surgical assessment, while balancing maternal stabilization and fetal considerations. ^[98]C4

Chronic kidney disease and kidney transplantation

Renal dysfunction both complicates hypercalcemia management and may indicate an alternative diagnosis. Milk-alkali syndrome is characterized by hypercalcemia, metabolic alkalosis, and renal failure; in an 83-year-old man, prolonged consumption of 1.5–2.0 L/day of calcium-containing thermal water caused persistent hypercalcemia and renal insufficiency, which normalized after the exposure stopped. ^[205]C Patients with kidney disease should therefore undergo a detailed review of calcium, alkali, supplements, and unusual mineral-water exposures before attributing hypercalcemia to cancer. ^[205]C

In kidney-transplant recipients, tertiary hyperparathyroidism is a separate PTH-dependent cause of hypercalcemia. A TriNetX study compared parathyroidectomy with cinacalcet and examined the timing of surgery after transplantation; the study was motivated by evidence that parathyroidectomy may be superior to medical management for hypercalcemia and renal-allograft preservation. ^[207]D The 2025 Cochrane review addressed phosphate binders for CKD-mineral and bone disorder, assessing benefits, harms, and comparative effects of binders through 16 December 2024; this evidence concerns phosphate control in CKD and should not be interpreted as direct treatment evidence for hypercalcemia of malignancy. ^[104]A1a

Parathyroid carcinoma and hereditary endocrine syndromes

Parathyroid carcinoma is a rare malignancy characterized commonly by unregulated PTH secretion, severe hypercalcemia, and, in advanced disease, complications from tumor dissemination; available management evidence is largely derived from case reports, case series, and registry studies. Surgical resection remains important for localized and metastatic disease, with newer approaches also emerging. ^[48]D5 Severe skeletal and renal manifestations may be presenting features: a young man developed a pathological fracture after minimal trauma in the setting of parathyroid carcinoma-associated hyperparathyroidism. ^[34]C4

Marked biochemical abnormalities do not establish carcinoma. A series and literature review described three women with symptomatic primary hyperparathyroidism and PTH concentrations of 755–3,547.4 pg/mL whose lesions were adenomas without histopathologic malignancy. ^[105]C4 Conversely, giant parathyroid adenomas—defined as glands weighing more than 3.5 g—formed 78 of 561 surgically treated cases; the mean age was 42 years, 65% were female, and bone pain and renal calculi were frequent presentations. ^[159] MEN1-associated primary hyperparathyroidism is often the earliest MEN1 manifestation; expert review recommends surgery for patients with MEN1 and hypercalcemia, commonly before age 50, with timing influenced by calcium concentration and renal or skeletal complications. ^[28]D5 A case report illustrates that MEN1 may present with hypercalcemia, hypophosphatemia, and concurrent gastrointestinal and pituitary-region disease. ^[170]C

Hematologic malignancy and unusual cancer mimics

Multiple myeloma commonly presents with combinations of anemia, bone pain, renal injury, fatigue, hypercalcemia, and weight loss. ^[100]D5 A report of biclonal IgA myeloma documented extreme PTH-independent hypercalcemia reaching 17.4 mg/dL, with hyperphosphatemia, no marrow osteoclasts, and no osteolytic lesions; calcium normalized within eight days with supportive care and remained normal for nine months. ^[160]C These findings emphasize that severe hypercalcemia in myeloma may not follow the classical osteolytic pattern. ^[160]C

Other nonmalignant mimics include IgG4-related disease presenting with acute kidney injury and calcium 3.69 mmol/L, which improved with prednisone and supportive care. ^[204]C High-volume gluteal PMMA injections have been associated with hypercalcemia, hypercalciuria, nephrolithiasis, and renal insufficiency; in a series of 12 women, injected volumes ranged from 150–900 mL. ^[202]C CYP24A1 loss-of-function can cause persistent vitamin-D-mediated hypercalcemia with nephrocalcinosis and nephrolithiasis despite parathyroidectomy. ^[52]C4 Experimental mouse data further indicate tissue-specific intestinal and renal CYP24A1 effects on vitamin-D and mineral homeostasis, but these findings are not direct human treatment evidence. ^[206]D

Denosumab discontinuation and dialysis

Rebound hypercalcemia is a rare, non-PTH-dependent complication after denosumab cessation. It occurred in a 47-year-old man followed after surgery for parathyroid carcinoma and resolved after denosumab was restarted. ^[102]C4 Calcium should therefore be monitored after discontinuation, particularly when high bone turnover or complex endocrine disease is present. ^[102]C4 Hemodialysis successfully corrected catastrophic iatrogenic hypercalcemia with acute kidney injury in a cat after calcium-gluconate overdose, but this veterinary report cannot establish human indications or dosing. ^[203]C

Overall prognosis

Hypercalcemia of malignancy (HCM) is a major adverse prognostic marker, generally indicating advanced tumor burden, biologically aggressive disease, or both. In a national inpatient analysis of adults hospitalized with solid cancer and HCM, approximately 50% died within 1 month of diagnosis, although inpatient administrative cohorts may overrepresent patients with severe illness. ^[3]B3b In a hospital-based series of patients with cancer-associated hypercalcemia treated with intravenous diphosphonates, median survival was 64 days (range, 12–1,955+ days). ^[111]C4 A separate cohort of patients with squamous-cell carcinoma and a first episode of cancer-associated hypercalcemia reported the same median survival of 64 days (range, 1–197 days). ^[14]B3b

Prognosis varies substantially according to tumor type, disease extent, calcium severity, nutritional status, renal function, and the feasibility of effective anticancer treatment. HCM should therefore be interpreted as a marker of the overall clinical state rather than as an isolated laboratory abnormality. ^[111]C4[209]

Prognostic factors and mortality risk

The degree of calcium elevation is consistently associated with poorer outcomes. In the diphosphonate-treated cohort, corrected calcium above 2.83 mmol/L was independently associated with inferior survival (HR 2.21). ^[111]C4 Among patients with squamous-cell malignancies, corrected calcium above 3.0 mmol/L independently predicted worse survival (HR 1.45; 95% CI, 1.05–2.01). ^[14]B3b Hypoalbuminemia was also an adverse factor in both analyses: albumin below 35.5 g/L was associated with shorter survival in the broader cancer-associated hypercalcemia cohort (HR 2.41), while hypoalbuminemia independently predicted mortality in the squamous-cell carcinoma cohort (HR 1.4). ^{[111]C4[14]B3b}

Additional adverse features identified in the diphosphonate-treated population included squamous-cell carcinoma (HR 2.64) and bone metastases (HR 1.44). ^[111]C4 In the squamous-cell carcinoma study, brain metastases were associated with markedly poorer survival (HR 2.58; 95% CI, 1.03–6.45). ^[14]B3b A multicenter study of hospitalized oncology patients found a short median follow-up of 3.5 weeks (IQR, 1.1–11.5), emphasizing the high early mortality of this clinical presentation; it evaluated clinical and laboratory predictors of death in 154 patients. ^[209]

Tumor-specific outcomes

In newly diagnosed multiple myeloma, hypercalcemia was present in 16.8% of 357 patients and was associated with higher β2-microglobulin, creatinine, phosphorus, uric acid, and procollagen I N-terminal propeptide levels, suggesting greater disease burden and renal or skeletal involvement. ^[7]B3b The study specifically concluded that humoral effects and bone damage were linked to poor outcomes. ^[7]B3b In another retrospective series of 338 patients with symptomatic stage II–III myeloma, clinical outcomes were examined in the context of hematopoietic stem-cell transplantation, conventional chemotherapy, and newer treatment strategies; the cohort reflects the prognostic influence of treatment era and disease stage when interpreting myeloma survival data. ^[112]B2b

Among diffuse large B-cell lymphoma patients, hypercalcemia at diagnosis occurred in 23% of de novo cases and 26% of transformed indolent lymphomas. ^[9]B3b In de novo disease, hypercalcemia was strongly associated with high-risk clinical features, particularly a high International Prognostic Index, and with a short interval from diagnosis to treatment. ^[9]B3b These findings support the use of hypercalcemia as a warning sign for aggressive lymphoma biology, although hypercalcemia alone should not replace formal lymphoma risk assessment. ^[9]B3b

In advanced or metastatic head and neck squamous-cell carcinoma, hypercalcemia was defined as albumin-corrected calcium above 2.6 mmol/L (10.4 mg/dL) in a bicentric retrospective study of patients receiving chemotherapy. ^[8]B3b The study evaluated overall survival, phenotypes, mechanisms, and treatment options, reflecting the clinically important prognostic role of HCM in this population. ^[8]B3b Gynecologic malignancy cohorts likewise demonstrate poor outcomes: hypercalcemia occurred in 5% of 5,260 patients, and 82% of affected patients had mild hypercalcemia; calcium severity was associated with survival. ^[18]B3b

A notable disease-specific exception is small-cell carcinoma of the ovary, hypercalcemic type (SCCOHT), a rare, rapidly lethal tumor affecting young women. ^[113]C4 In a prospective multicenter cohort of 44 women, patients received cytoreductive surgery and four to six cycles of PAVEP chemotherapy; those achieving complete response proceeded to high-dose chemotherapy with stem-cell support and pelvic radiotherapy. ^[113]C4 The study was designed to assess event-free survival and to confirm whether this dose-intensive strategy improves outcomes, but its applicability is limited to this rare tumor and selected patients able to receive intensive therapy. ^[113]C4

Complications and related outcomes

HCM may coexist with acute kidney injury, dehydration, altered mental status, cardiac complications, and hospitalization, all of which can worsen short-term prognosis. In an emergency-department study, malignancy was the most common identified cause of hypercalcemia (36.4%), and normal renal function was present in only 23.4% of patients. ^[208] A large inpatient study of calcium levels also evaluated in-hospital and long-term mortality, supporting calcium concentration and its evolution during hospitalization as clinically meaningful risk markers, although it was not restricted to HCM. ^[155]

Hypercalcemia complicated by acute pancreatitis appears particularly severe. A systematic review identified 37 reported cases; mean presenting corrected calcium was 14.5 mg/dL, and parathyroid carcinoma and multiple myeloma each accounted for 21.6% of cases. ^[15]C4 Because the evidence consisted primarily of published cases, outcome estimates are subject to substantial selection and reporting bias. ^[15]C4

PTHrP-mediated hypercalcemia is another high-risk phenotype. A series of 138 patients with persistent hypercalcemia and simultaneously elevated PTHrP evaluated malignant and benign causes and survival. ^[19]C4 A newer study specifically examined whether serum PTHrP levels above 1.1 pmol/L in patients with calcium above 10 mg/dL were associated with mortality after malignancy diagnosis, PTHrP measurement, and at 5 years; the findings are intended to clarify whether PTHrP concentration provides prognostic information beyond calcium itself. ^[11]B3b

Practical interpretation

The combination of marked hypercalcemia, hypoalbuminemia, renal dysfunction, metastatic disease, squamous histology, brain metastases, or high-risk hematologic features identifies patients at especially high risk of early death. ^{[111]C4[14]B3b[7]B3b[9]B3b[209]} Prognostic assessment should include functional status, symptom burden, reversibility of precipitants, tumor-directed treatment options, and the patient’s goals of care; calcium correction alone does not necessarily change the underlying cancer prognosis. ^{[3]B3b[111]C4}

Scope of the available evidence

The supplied evidence set does not contain a dedicated guideline, systematic review, clinical trial, or consensus statement focused on hypercalcemia of malignancy. The references are predominantly disease-specific oncology guidelines or guideline updates addressing cancer diagnosis, staging, systemic therapy, surveillance, survivorship, or psychosocial care rather than the diagnostic thresholds, severity classification, emergency treatment, monitoring, or prevention of malignancy-associated hypercalcemia. ^{[211][212][115]A1c[116]A1c[117]A1c[130]A1c[131]A1c[213][118]A1c[119]A1c[132]A1c[133]A1c[121]A1c[128]D5[122]A1c[123]A1c[124]A1c[125]A1c[126]A1c[127]A1c}

Accordingly, these references cannot substantiate specific recommendations for corrected or ionized calcium thresholds, intravenous fluid selection or rate, calcitonin, bisphosphonates, denosumab, glucocorticoids, dialysis, cardiac monitoring, renal-dose adjustment, or treatment response targets. ^{[211][212][115]A1c[116]A1c[117]A1c[130]A1c[131]A1c[213][118]A1c[119]A1c[132]A1c[133]A1c[121]A1c[128]D5[122]A1c[123]A1c[124]A1c[125]A1c[126]A1c[127]A1c}

Cancer-specific guideline context

Several supplied guidelines concern malignancies in which hypercalcemia may be clinically relevant, but their provided abstracts do not describe hypercalcemia management. The pleural mesothelioma guideline provides recommendations for evaluation and treatment of pleural mesothelioma, which represents approximately 85% of mesotheliomas. ^[211] The breast cancer guideline addresses carcinoma in situ, invasive, Paget, phyllodes, inflammatory, recurrent, and stage IV breast cancer, with treatment strategies stratified by tumor biology and clinical factors; the supplied abstract does not report a hypercalcemia algorithm. ^[115]A1c The cutaneous melanoma guideline addresses diagnosis, treatment, and follow-up and emphasizes stage, tumor size, phenotypic and medical risk factors, genetic predisposition, and environmental factors; it does not provide hypercalcemia-specific recommendations in the supplied evidence. ^[116]A1c

The acute myeloid leukemia guideline addresses diagnosis and treatment in adults with AML and summarizes updates involving monitoring, clinical trials, and biologic prognostic factors, but the supplied abstract does not specify management of malignancy-associated hypercalcemia. ^[117]A1c The multiple myeloma guidelines describe individualized diagnosis, workup, treatment, and follow-up for newly diagnosed and previously treated disease, while the ASCO living guideline addresses treatment of multiple myeloma; neither supplied abstract states calcium thresholds or a hypercalcemia treatment sequence. ^{[122]A1c[213]}

The lung cancer references provide living-guideline recommendations for stage IV NSCLC with and without driver alterations, and NCCN recommendations for advanced or metastatic NSCLC with actionable biomarkers; their stated focus is systemic therapy selection and targeted treatment rather than hypercalcemia management. ^{[130]A1c[131]A1c[133]A1c} The small-cell lung cancer guideline addresses diagnostic workup, staging, systemic therapy, and radiation-treatment updates without a hypercalcemia-specific protocol in the supplied abstract. ^[124]A1c

Additional disease-specific references address bladder cancer, prostate cancer, vaginal cancer, cervical cancer, Hodgkin lymphoma, and soft-tissue sarcoma. Their supplied abstracts focus respectively on non-muscle-invasive bladder cancer, nonmetastatic prostate cancer updates, vaginal-cancer workup and treatment, cervical-cancer staging and systemic therapy, adult classic Hodgkin lymphoma, and surgical or systemic therapy for soft-tissue sarcoma; none supplies a malignancy-associated hypercalcemia algorithm. ^{[118]A1c[119]A1c[121]A1c[125]A1c[126]A1c[123]A1c}

Supportive-care and implementation relevance

The survivorship guideline covers common physical and psychosocial problems after adult-onset cancer, wellness, healthy lifestyle, and care coordination, but the supplied abstract does not identify hypercalcemia as a specific survivorship intervention. ^[212] The distress-management guideline addresses identification, referral, and treatment of psychosocial problems in patients with cancer and does not provide biochemical management recommendations. ^[132]A1c The ESMO EnLiST framework standardizes designation of systemic-therapy lines in solid tumors through a multidisciplinary Delphi consensus process; it may support consistent documentation of anticancer treatment sequence but does not define hypercalcemia treatment. ^[128]D5

Practical interpretation for this wiki section

Based solely on the supplied references, the evidence supports using current disease-specific oncology guidelines to guide treatment of the underlying malignancy, with treatment choice determined by tumor type, stage, biomarkers, prior therapy, and other clinical factors when those issues are addressed by the relevant guideline. ^{[115]A1c[118]A1c[119]A1c[130]A1c[131]A1c[133]A1c[211][213][122]A1c[123]A1c[124]A1c[125]A1c[126]A1c} However, the references provided here do not support a stand-alone evidence-based protocol for diagnosing or treating hypercalcemia of malignancy. ^{[211][212][115]A1c[116]A1c[117]A1c[130]A1c[131]A1c[213][118]A1c[119]A1c[132]A1c[133]A1c[121]A1c[128]D5[122]A1c[123]A1c[124]A1c[125]A1c[126]A1c[127]A1c}

Any detailed calcium thresholds, drug recommendations, renal-function precautions, monitoring schedule, or escalation pathway should therefore be added only after incorporating a directly relevant hypercalcemia-of-malignancy guideline or primary evidence source. ^{[211][212][115]A1c[116]A1c[117]A1c[130]A1c[131]A1c[213][118]A1c[119]A1c[132]A1c[133]A1c[121]A1c[128]D5[122]A1c[123]A1c[124]A1c[125]A1c[126]A1c[127]A1c}

Scope of prevention

Prevention of hypercalcemia of malignancy (HCM) depends primarily on controlling the underlying cancer and identifying patients at risk for osteolytic or osteoblastic skeletal disease. The updated evidence base is dominated by studies of bone-modifying agents (BMAs) used to prevent skeletal-related events (SREs), cancer-treatment-induced bone loss, or fractures; these studies should not be interpreted as direct evidence that BMAs prevent every episode of HCM. ^{[61]A1a[135]A1a[174][214]}

Baseline assessment and supportive care

Patients considered for prolonged antiresorptive therapy should undergo individualized assessment of fracture risk, skeletal disease, renal function, calcium status, vitamin D status, dental health, and the anticipated duration of therapy. The reviewed literature identifies calcium and vitamin D supplementation as part of supportive management in bone-protective treatment protocols, including denosumab treatment in recurrent or refractory osteosarcoma. ^{[135]A1a[140]C4} Myeloma guidance continues to address bisphosphonates, denosumab, and osteonecrosis as central components of bone-disease management. ^[214]

Dental evaluation and preventive dental care are particularly important because medication-related osteonecrosis of the jaw (MRONJ) is a recognized concern during BMA treatment and is relevant when deciding treatment duration or discontinuation. ^{[61]A1a[134]A1c[214][222]} Treatment plans should therefore incorporate oral-hygiene optimization, avoidance of unnecessary invasive dental procedures during active therapy when feasible, and coordinated dental–oncology follow-up. ^{[134]A1c[214][222]}

Choosing and monitoring antiresorptive therapy

Denosumab and bisphosphonates are established options for reducing skeletal complications in patients with bone metastases, although their comparative benefits and harms vary by cancer type, endpoint, and certainty of evidence. ^[61]A1a In breast-cancer bone metastases, a systematic review comparing denosumab with bisphosphonates evaluated SREs, fractures, radiation or surgery, renal and metabolic adverse events, MRONJ, and serious or treatment-related toxicity; the evidence included four unique studies, comprising three randomized trials and one retrospective cohort. ^[61]A1a

For non-metastatic prostate cancer treated with androgen-deprivation therapy (ADT), a 2026 systematic review included 26 randomized controlled trials: 17 intravenous-bisphosphonate trials, 5 oral-bisphosphonate trials, and 2 denosumab trials, with 2 trials including both an oral bisphosphonate and denosumab. ^[174] Oral bisphosphonates did not demonstrate a clear reduction in fractures at 12 months, with a reported risk ratio of 0.57 (95% CI, 0.10–3.23) and very low certainty of evidence. ^[174] This uncertainty supports risk-adapted rather than automatic antiresorptive treatment for every man receiving ADT. ^[174]

In early breast cancer, BMAs are used to mitigate cancer-treatment-induced bone loss, and updated guidance addresses treatment initiation, timing, and agent selection. ^[134]A1c A systematic review in non-metastatic breast cancer evaluated bisphosphonates, denosumab, calcium, and vitamin D for effects on bone mineral density, fractures, bone-turnover markers, and safety outcomes. ^[135]A1a Denosumab should not presently be assumed to provide anticancer benefit in early breast cancer: the randomized GeparX study found no improvement in pathological complete response, and long-term outcomes were assessed for invasive disease-free, distant disease-free, overall, and locoregional recurrence-free survival. ^[144]A1b A separate randomized window-of-opportunity study investigated denosumab as an immune and biological modulator in HER2-negative early breast cancer, reflecting an investigational rather than established prevention strategy. ^[145]A1b

Disease-specific prevention and surveillance

In multiple myeloma, updated 2025 consensus guidance specifically reviews zoledronic acid, pamidronate, denosumab, and osteonecrosis for myeloma bone disease. ^[214] In metastatic castration-sensitive prostate cancer, the role of BMAs remains unclear; a retrospective study characterized symptomatic skeletal events among 318 patients with bone metastases treated with denosumab. ^[218] Real-world studies have also examined denosumab-associated survival and SRE outcomes in Asian men with metastatic castration-resistant prostate cancer, in lung-cancer populations with bone metastases, and in stage IV lung adenocarcinoma receiving denosumab 120 mg subcutaneously every 4 weeks ± 7 days. ^{[220][221][223]} Because these are observational datasets, they support risk stratification and hypothesis generation rather than definitive causal treatment recommendations. ^{[218][220][221][223]}

Duration, discontinuation, and future directions

The optimal duration of denosumab for bone metastases remains uncertain because prolonged exposure may reduce skeletal complications but increases cumulative concern regarding MRONJ. ^[222] A retrospective cohort of 178 patients who discontinued denosumab after at least 6 doses evaluated the incidence, timing, and predictors of subsequent symptomatic skeletal events; a landmark analysis also examined patients treated for at least 2 years. ^[222] Discontinuation should therefore be planned rather than treated as an automatically risk-free endpoint, with reassessment of skeletal disease activity, fracture risk, dental status, and alternative antiresorptive strategies. ^[222]

Future research should prioritize randomized comparisons of denosumab, intravenous and oral bisphosphonates; validated biomarkers for skeletal-event and HCM risk; optimal treatment intervals; safe discontinuation or transition protocols; and integration of BMAs with systemic anticancer therapy. ^{[61]A1a[135]A1a[174][214][222]} RANKL inhibition is also being investigated as an immune or tumor-microenvironment intervention in renal-cell carcinoma, breast cancer, dermatologic malignancies, osteosarcoma, and giant-cell tumor of bone, but current evidence includes phase II, observational, mechanistic, or meta-analytic studies and should not be extrapolated to routine HCM prevention. ^{[62]C4[145]A1b[217][219][140]C4[146]A1a[215][216]} In giant-cell tumor of bone, updated recommendations continue to position surgery as the main treatment and reserve denosumab for unresectable disease or situations in which resection would cause severe morbidity. ^[215] Perioperative denosumab remains an area of uncertainty because its association with local recurrence after surgical management has produced conflicting findings. ^[146]A1a Denosumab has also been studied in recurrent or refractory osteosarcoma, with calcium and vitamin D supplementation incorporated into the treatment protocol, but single-arm phase II evidence is insufficient to establish preventive use for HCM. ^[140]C4